Aumolertinib (EQ143, HS-10296) is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets both EGFR-sensitizing and T790M resistance mutations, with high selectivity over wild-type EGFR. Aumolertinib was in-licensed from Hansoh Pharmaceuticals.
Pipeline
Our Catalog of Medicines in Development
By leveraging cutting-edge technology, rigorous and validated science and strategic partnerships across the healthcare ecosystem, we’re aiming to develop medicines more efficiently and cost-effectively than ever before. We believe it’s possible to greatly expand access to new, high-quality, patent-protected therapeutics.
EQRx’s growing portfolio of medicines in development is targeting diseases and therapeutic classes that create a high cost burden to patients and society. Our clinical stage programs span several indications in oncology and immune-inflammatory diseases.
Aumolertinib
EQ143, HS-10296
EGFR
Aumolertinib
EQ143, HS-10296
EGFR
Sugemalimab
EQ165, CS1001
PD-L1
Sugemalimab
EQ165, CS1001
PD-L1
Sugemalimab (EQ165, CS1001) is a monoclonal antibody targeting programmed death-ligand 1 (PD-L1). Sugemalimab was in-licensed from CStone Pharmaceuticals.
Nofazinlimab
EQ176, CS1003
PD-1
Nofazinlimab
EQ176, CS1003
PD-1
Nofazinlimab (EQ176, CS1003) is a monoclonal antibody targeting programmed cell death protein 1 (PD-1). Nofazinlimab was in-licensed from CStone Pharmaceuticals.
Lerociclib
EQ132
CDK4/6
Lerociclib
EQ132
CDK4/6
Lerociclib (EQ132) is a novel, oral, potent and selective small molecule cyclin-dependent kinase (CDK) 4/6 inhibitor. Lerociclib was in-licensed from G1 Therapeutics.
EQ121
JAK1
EQ121
JAK1
EQ-121 is a novel, highly selective janus kinase-1 (JAK-1) inhibitor. EQ121 was in-licensed from Lynk Pharmaceuticals.